Final Recommendation Statement
Syphilis Infection in Nonpregnant Adults and Adolescents: Screening
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Jun 07, 2016Return to Recommendation
The U.S. Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific clinical preventive services for patients without obvious related signs or symptoms.
It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment.
The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.
The number of cases of primary and secondary syphilis have increased since 2000. In 2014, 19,999 cases (6.3 cases per 100,000 persons) of primary and secondary syphilis were reported in the United States.1 Left untreated, syphilis can progress to late-stage disease in approximately 15% of persons who are infected.2 Consequences of late-stage syphilis include development of inflammatory lesions throughout the body (eg, aortitis, gummatous lesions, and osteitis), which can lead to cardiovascular or organ dysfunction. Syphilis infection of the central nervous system (neurosyphilis) can occur at any stage of disease and can result in blindness, paresis, tabes dorsalis, and dementia. Syphilis infection also increases the risk for acquiring or transmitting HIV infection.
The USPSTF addresses screening for syphilis in pregnant women in a separate recommendation statement.3
There are numerous screening tests for syphilis. Most common is a combination of nontreponemal and treponemal antibody tests. The USPSTF found convincing evidence that screening algorithms with high sensitivity and specificity are available to accurately detect syphilis.
Benefits of Early Detection and Treatment
The USPSTF found convincing evidence that treatment with antibiotics can lead to substantial health benefits in nonpregnant persons who are at increased risk for syphilis infection by curing syphilis infection, preventing manifestations of late-stage disease, and preventing sexual transmission to others.
Harms of Early Detection and Treatment
The USPSTF found no direct evidence on the harms of screening for syphilis in nonpregnant persons who are at increased risk for infection. Potential harms of screening include false-positive results that require clinical evaluation, unnecessary anxiety to the patient, and the potential stigma of having a sexually transmitted infection. The harms of antibiotic treatment are well established, and the magnitude of these harms is no greater than small.
The USPSTF concludes with high certainty that the net benefit of screening for syphilis infection in nonpregnant persons who are at increased risk for infection is substantial.
This recommendation applies to asymptomatic, nonpregnant adults and adolescents who are at increased risk for syphilis infection. Screening for syphilis in nonpregnant populations is an important public health approach to preventing the sexual transmission of syphilis and subsequent vertical transmission of congenital syphilis.
Assessment of Risk
The USPSTF recommends screening for syphilis in persons who are at increased risk for infection. Based on 2014 surveillance data,1 men who have sex with men (MSM) and men and women living with HIV have the highest risk for syphilis infection; 61.1% of cases of primary and secondary syphilis occurred among MSM, and approximately one-half of all MSM diagnosed with syphilis were also coinfected with HIV. One study found that rates of syphilis coinfection were 5 times higher in MSM living with HIV compared with men living with HIV who do not have sex with men.4 Based on older study data from northern California, the adjusted relative risk for syphilis infection in persons living with HIV (vs those without HIV) was 86.0 (95% CI, 78.6 to 94.1); 97% of those living with HIV and with incident syphilis were male.5
When deciding which other persons to screen for syphilis, clinicians should be aware of the prevalence of infection in the communities they serve, as well as other sociodemographic factors that may be associated with increased risk of syphilis infection. Factors associated with increased prevalence that clinicians should consider include history of incarceration, history of commercial sex work, certain racial/ethnic groups, and being a male younger than 29 years, as well as regional variations that are well described. Men accounted for 90.8% of all cases of primary and secondary syphilis in 2014. Men aged 20 to 29 years had the highest prevalence rate, nearly 3 times higher than that in the average US male population.1 Syphilis prevalence rates are also higher in certain racial/ethnic groups (among both men and women); in 2014, prevalence rates of primary and secondary syphilis were 18.9 cases per 100,000 black individuals, 7.6 cases per 100,000 Hispanic individuals, 7.6 cases per 100,000 American Indian/Alaska Native individuals, 6.5 cases per 100,000 Native Hawaiian/Pacific Islander individuals, 3.5 cases per 100,000 white individuals, and 2.8 cases per 100,000 Asian individuals.1 The southern United States comprises the largest proportion of syphilis cases (41%); however, the case rate is currently highest in the western United States (7.9 cases per 100,000 persons). Metropolitan areas in general have increased prevalence rates of syphilis.1 Risk factors for syphilis often do not present independently and may frequently overlap. In addition, local prevalence rates may change over time, so clinicians should be aware of the latest data and trends for their specific population and geographic area.
Although direct evidence on screening among nonpregnant persons who are not at increased risk for syphilis infection is lacking, based on the established test performance characteristics of current screening tests and the low prevalence rate of syphilis in this population, the yield of screening is likely low. Therefore, screening in this population may result in high false-positive rates and overtreatment.
Current screening tests for syphilis rely on detection of antibodies rather than direct detection of the organism. Screening for syphilis infection is a 2-step process involving an initial nontreponemal test (Venereal Disease Research Laboratory [VDRL] or rapid plasma reagin [RPR] test) followed by a confirmatory treponemal antibody detection test (fluorescent treponemal antibody absorption [FTA-ABS] or Treponema pallidum particle agglutination [TPPA] test). A reverse sequence screening algorithm has been developed in which an automated treponemal test (such as enzyme-linked, chemiluminescence, or multiplex flow immunoassays) is performed first, followed by a nontreponemal test. If the test results are discordant in the reverse sequence algorithm, a second treponemal test (preferably using a different treponemal antibody) is performed.6 There is limited evidence on the accuracy of screening using the reverse sequence algorithm. Findings from 2 studies suggest that using a reverse sequence algorithm may detect additional cases of syphilis missed by the usual algorithm.7 However, the clinical significance of these additional cases is unclear, and more studies are needed to better understand the implications of using a reverse sequence algorithm for screening in a primary care setting. Newer screening technologies that include rapid syphilis tests are also currently emerging. These tests have the potential to be performed in nontraditional and nonclinical settings; however, more evidence is needed on the effectiveness of these tests as part of a screening program in a primary care setting.
The optimal screening frequency for persons who are at increased risk for syphilis infection is not well established. Men who have sex with men or persons living with HIV may benefit from more frequent screening. Initial studies suggest that detection of syphilis infection in MSM or persons living with HIV improves when screening is performed every 3 months compared with annually.7
In its 2015 guidelines on the treatment of sexually transmitted diseases, the Centers for Disease Control and Prevention (CDC) recommends parenteral penicillin G benzathine for the treatment of syphilis. Dosage and route may vary depending on the stage of disease and patient characteristics. To obtain the most up-to-date information, clinicians are encouraged to access the CDC website.8
Additional Approaches to Prevention
Public health agencies and local health departments have a critical role in the prevention and treatment of syphilis. Local health departments are often responsible for investigating incident cases of syphilis and identifying potential contacts who may need further testing or treatment. Primary care clinicians should be aware of applicable local public health laws and reporting requirements for syphilis cases.
Persons who are at risk for or have been diagnosed with syphilis infection may engage in behavior that increases their risk for other sexually transmitted infections. The USPSTF has made a separate recommendation on screening for syphilis in pregnant women, as well as screening for HIV, gonorrhea, and chlamydia in sexually active adolescents and adults and behavioral counseling interventions to prevent sexually transmitted infections (available at www.uspreventiveservicestaskforce.org).
Although testing for syphilis in persons living with HIV may be part of HIV management care provided in a specialty setting, screening for syphilis is often conducted in primary care settings, and primary care clinicians are encouraged to routinely screen their patients who are living with HIV.
Research Needs and Gaps
Studies are needed that directly evaluate the effectiveness of screening for syphilis on related morbidity and mortality in other high-risk populations, in addition to MSM and persons living with HIV, as well as studies that help identify optimal screening intervals. Studies in adolescent populations are particularly needed. In addition, studies that evaluate the effectiveness of risk assessment instruments or other methods to identify persons who are at increased risk and who may benefit from screening are needed. Further, studies on the diagnostic accuracy of reverse sequence screening algorithms in well-defined patient populations are needed, as well as studies on the interpretation and management of discrepant serology results (such as a positive automated treponemal test, negative nontreponemal test, and positive second treponemal test).
Burden of Disease
Syphilis is a chronic, systemic infectious disease caused by the bacterium T pallidum. Left untreated, syphilis can progress through the following stages: primary, secondary, latent (early and late), and tertiary disease. Syphilis infection of the nervous system (neurosyphilis) can occur at any stage. Although not always present or noticed by patients, manifestations of primary syphilis include ulcers or a single chancre at the infection site. Manifestations of secondary syphilis include rash, mucocutaneous lesions, and lymphadenopathy. Manifestations of tertiary syphilis include inflammatory lesions of the cardiovascular system (eg, aortitis or coronary vessel disease), skin (eg, gummatous lesions), bone (eg, osteitis), or other tissue. Rarely, other structures may be involved. Manifestations of early neurosyphilis include cranial nerve dysfunction, meningitis stroke, acute altered mental status, and auditory or ophthalmic abnormalities; late neurologic manifestations include tabes dorsalis and general paresis and can occur 10 to 30 years after initial infection.9 Syphilis can be sexually transmitted during the early stages of infection (primary, secondary, and early-latent syphilis); reported transmission rates range from 15.9% to 30.3%.10, 11 Congenital or vertical transmission may occur at any stage. Syphilis infection increases the risk for acquiring or transmitting HIV if exposed;1 among persons living with HIV, syphilis infection is associated with a subsequent increase in HIV viral load and decrease in CD4 cell counts.12-14
In 2014, the total number of syphilis cases reported for all stages (including 458 cases of congenital syphilis) and all ages in the United States was 63,450, which is a 12.3% increase from the previous year. The case count (19,999 cases) and case rate (6.3 cases per 100,000 persons) of primary and secondary syphilis were the highest reported since 1994. All but 24 cases occurred in persons 15 years and older. Among men, the rate of primary and secondary syphilis has increased every year since 2000; however, among women, the rate of primary and secondary syphilis has fluctuated between 0.8 and 1.7 cases per 100,000 since 2000. During 2013–2014, the rate among men increased 14.4%, from 10.2 to 11.7 cases per 100,000; among women, the rate increased 22.7%, from 0.9 to 1.1 cases per 100,000.1 The majority of cases of primary and secondary syphilis still occur among MSM. In 2014, there were 23,541 cases (7.4 cases per 100,000 persons) of late and late-latent syphilis.1 More recently, the CDC has reported an increase in cases of ocular syphilis, with more than 200 cases reported in 20 states since 2014, the majority of which have been among MSM living with HIV.15
Scope of Review
The USPSTF commissioned a systematic review7, 16 of studies published since it previously reviewed the evidence on this topic in 2004.17 The USPSTF also considered evidence from its previous evidence review. Included studies had to be applicable to the United States, as determined by the similarity of study participants and availability of health care services and screening tests in the study setting. The review focused on screening for syphilis infection in asymptomatic, nonpregnant adults and adolescents, including patients coinfected with other sexually transmitted infections (such as HIV).
Accuracy of Screening Tests
Screening for syphilis is usually a 2-step process. A nontreponemal test (RPR or VDRL) is performed first, followed by a treponemal test (TPPA or FTA-ABS) if the first nontreponemal test result is positive. Positive results on both tests indicate past or present syphilis infection. Estimated sensitivities of the RPR and VDRL tests are 86% and 78%, respectively, for detecting primary syphilis infection; 100% for detecting secondary syphilis infection; and 98% and 96% for detecting latent syphilis infection, respectively.7 Specificity ranges from 85% to 99% and may be reduced in persons who have a preexisting condition (ie, collagen vascular disease, pregnancy, intravenous drug use, advanced malignancy, tuberculosis, malaria, or viral and rickettsial diseases) that may produce false-positive results.7 The TPPA and FTA-ABS tests have a sensitivity of 88% and 84%, respectively, for detecting primary syphilis infection and almost 100% for detecting other stages, and a specificity of 96% to 97%, respectively.7
Screening yield using the 2-step process (RPR followed by confirmatory FTA-ABS) can be estimated using test characteristics and the incidence of syphilis infection in a given population. For example, in the general population (assuming prevalence of 5 cases per 100,000 persons, RPR sensitivity of 91% and specificity of 95%, and FTA-ABS sensitivity of 92% and specificity of 96%), more than 24,000 patients would have to be screened to detect a single case of syphilis infection; further, 200 per 100,000 persons screened would have false-positive results. In a high-risk population (assuming prevalence of 12%, RPR sensitivity of 91% and specificity of 95%, and FTA-ABS sensitivity of 92% and specificity of 96%), 10 patients would have to be screened to detect a single case of syphilis infection; almost 2,000 per 100,000 persons screened would have false-negative results.7
More recently, automated treponemal tests have been developed, including enzyme-linked, chemiluminescence, and multiplex flow immunoassays. Reported sensitivity ranges from 64% to 100% (depending on stage of disease and type of test used), and specificity ranges from 95.4% to 99.9%.7 These automated treponemal tests are often used in a reverse sequence screening algorithm, in which an automated treponemal test is performed first, followed by a nontreponemal test (quantitative) if the first automated treponemal test result is positive. A positive result on both the automated treponemal and the nontreponemal test indicates past or present syphilis infection. If the result of the automated treponemal test is positive but the nontreponemal test result is negative, a second treponemal test (TPPA, FTA-ABS, or other) is performed; a positive result on the second treponemal test indicates past or present syphilis infection.6
The USPSTF reviewed 2 studies that compared a reverse sequence screening algorithm with the traditional 2-step approach to screening.18, 19 One study was conducted in a low-prevalence US population19 and the other in a high-prevalence metropolitan area in Canada.18 Although both studies found that more cases were detected using the reverse sequence algorithm, use of the reverse sequence algorithm was associated with a higher false-positive rate. Overall, more studies on the reverse sequence screening algorithm are needed before definitive conclusions can be made on its effectiveness.
Effectiveness of Early Detection and Treatment
Based on CDC data,1 MSM and persons living with HIV are at highest risk for syphilis infection. In 2014, the majority of cases (61.1%) of primary and secondary syphilis occurred among MSM, and approximately one-half of all MSM diagnosed with syphilis were also coinfected with HIV. Increased prevalence of syphilis infection was also associated with certain racial/ethnic groups (black, Hispanic, American Indian/Alaska Native, and Native Hawaiian/Pacific Islander individuals had higher prevalence rates than white individuals, ranging from 6.5 to 18.9 vs 3.5 cases per 100,000 persons), geography (southern and western United States and metropolitan areas), and being a male younger than 29 years.1
The USPSTF found no recent studies on the direct effectiveness of screening for syphilis in asymptomatic, nonpregnant adults and adolescents to reduce complications or transmission of syphilis infection or acquisition of other sexually transmitted infections. Older clinical trials and observational studies and almost 50 years of clinical experience provide evidence that penicillin is effective in the treatment of syphilis infection.9 Penicillin G has long been an effective and accepted regimen for the treatment of all stages of syphilis infection, and new trials are focusing on antibiotics that are easier to administer or are alternatives for patients who are allergic to penicillin. Data on these alternative regimens are limited.9 Given the well-documented risk factors associated with increased prevalence of syphilis infection and the availability of accurate screening tests and treatment, the USPSTF found overall that screening for syphilis infection in persons who are at increased risk for infection is effective.
Potential Harms of Screening and Treatment
No studies directly evaluated the harms of screening. Potential harms of screening include opportunity costs to the clinician and patient (eg, time and resources) and false-positive results that may lead to stress, labeling, and further diagnostic workup. Harms of treatment include rare adverse drug-related effects, such as anaphylaxis due to penicillin allergy and the Jarisch-Herxheimer reaction (febrile reaction with headache, myalgia, and other symptoms), which may occur within the first 24 hours after any syphilis therapy.9
Estimate of Magnitude of Net Benefit
Overall, the USPSTF found convincing evidence that screening for syphilis infection in asymptomatic, nonpregnant persons who are at increased risk for infection provides substantial benefit. Accurate screening tests are available to identify syphilis infection in populations at increased risk. Effective treatment with antibiotics can prevent progression to late-stage disease, with small associated harms, providing an overall substantial health benefit.
Response to Public Comment
A draft version of this recommendation statement was posted for public comment on the USPSTF website from December 15, 2015 to January 18, 2016. A few comments sought clarification on which populations were considered to be at increased risk. The USPSTF added language to the Clinical Considerations section to clarify that men and women living with HIV who are not MSM are considered to be at increased risk for syphilis. In addition, men and women (and not just young men) who have identified sociodemographic risk factors associated with increased prevalence rates of syphilis may be considered at increased risk as well. In response to public comments, the USPSTF provided updated surveillance data from 2014. A few comments also requested additional information on various screening tests. However, these tests are outside the scope of this recommendation for various reasons (eg, diagnostic tests performed in symptomatic patients or newer technologies not yet evaluated for screening in a primary care setting).
This recommendation is consistent with and updates the 2004 USPSTF recommendation. The current recommendation statement includes updated information on prevalence and risk factors in the United States and data on newer screening tests and approaches. Screening for syphilis infection in pregnant women is now addressed in a separate recommendation statement.3
The CDC recommends at least annual screening for sexually active MSM with confirmatory testing for individuals with reactive serology. Persons living with HIV should be screened at least annually; more frequent screening may be appropriate based on individual risk behaviors and local epidemiology. The CDC also recommends syphilis screening in correctional facilities on the basis of the local area and institutional prevalence.9 The American Congress of Obstetricians and Gynecologists endorses the CDC’s guidelines.20 The HIV Medicine Association (part of the Infectious Diseases Society of America) recommends that all patients living with HIV be screened for syphilis on initiation of care and periodically thereafter, depending on risk.21 The American Academy of Family Physicians recommends screening for syphilis infection in persons who are at increased risk for infection.22
Members of the USPSTF at the time this recommendation was finalized† are Kirsten Bibbins-Domingo, PhD, MD, MAS (University of California, San Francisco); David C. Grossman, MD, MPH (Group Health Research Institute, Seattle, Washington); Susan J. Curry, PhD (University of Iowa, Iowa City); Karina W. Davidson, PhD, MASc (Columbia University, New York, New York); John W. Epling Jr, MD, MSEd (State University of New York Upstate Medical University, Syracuse); Francisco A.R. García, MD, MPH (Pima County Department of Health, Tucson, Arizona); Matthew W. Gillman, MD, SM (Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts); Diane M. Harper, MD, MPH, MS (University of Louisville, Kentucky); Alex R. Kemper, MD, MPH, MS (Duke University, Durham, North Carolina); Alex H. Krist, MD, MPH (Fairfax Family Practice Residency, Fairfax, Virginia, and Virginia Commonwealth University, Richmond); Ann E. Kurth, PhD, RN, MSN, MPH (Yale University, New Haven, Connecticut); C. Seth Landefeld, MD (University of Alabama at Birmingham); Carol M. Mangione, MD, MSPH (University of California, Los Angeles); William R. Phillips, MD, MPH (University of Washington, Seattle); Maureen G. Phipps, MD, MPH (Brown University, Providence, Rhode Island); and Michael P. Pignone, MD, MPH (University of North Carolina, Chapel Hill).
† For a list of current USPSTF members, go to www.uspreventiveservicestaskforce.org/Page/Name/our-members.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Financial Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. Authors followed the policy regarding conflicts of interest described at http://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures.
Copyright Notice: USPSTF recommendations are based on a rigorous review of existing peer-reviewed evidence and are intended to help primary care clinicians and patients decide together whether a preventive service is right for a patient’s needs. To encourage widespread discussion, consideration, adoption, and implementation of USPSTF recommendations, AHRQ permits members of the public to reproduce, redistribute, publicly display, and incorporate USPSTF work into other materials provided that it is reproduced without any changes to the work of portions thereof, except as permitted as fair use under the U.S. Copyright Act.
AHRQ and the U.S. Department of Health and Human Services cannot endorse, or appear to endorse, derivative or excerpted materials, and they cannot be held liable for the content or use of adapted products that are incorporated on other Web sites. Any adaptations of these electronic documents and resources must include a disclaimer to this effect. Advertising or implied endorsement for any commercial products or services is strictly prohibited.
This work may not be reproduced, reprinted, or redistributed for a fee, nor may the work be sold for profit or incorporated into a profit-making venture without the express written permission of AHRQ. This work is subject to the restrictions of Section 1140 of the Social Security Act, 42 U.S.C. § 1320b-10. When parts of a recommendation statement are used or quoted, the USPSTF Web page should be cited as the source.
1. 2014 Sexually transmitted disease surveillance. Centers for Disease Control and Prevention. http://www.cdc.gov/std/stats14/. Accessed May 6, 2016.
2. Syphilis: CDC fact sheet (detailed). Centers for Disease Control and Prevention. http://www.cdc.gov/std/syphilis/stdfact-syphilis-detailed.htm. Accessed April 12, 2016.
3. US Preventive Services Task Force. Screening for syphilis infection in pregnancy: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(10):705-9.
4. Yang B, Hallmark CJ, Huang JS, Wolverton ML, McNeese-Ward M, Arafat RR. Characteristics and risk of syphilis diagnosis among HIV-infected male cohort: a population-based study in Houston, Texas. Sex Transm Dis. 2013;40(12):957-63.
5. Horberg MA, Ranatunga DK, Quesenberry CP, Klein DB, Silverberg MJ. Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California. Sex Transm Dis. 2010;37(1):53-8.
6. Centers for Disease Control and Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011;60(5):133-7.
7. Cantor A, Nelson HD, Daeges M, Pappas M. Screening for Syphilis in Nonpregnant Adolescents and Adults: A Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 136. AHRQ Publication No. 14-05213-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
8. Sexually transmitted diseases (STDs): treatment. Centers for Disease Control and Prevention. http://www.cdc.gov/std/treatment/default.htm. Accessed May 3, 2016.
9. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.
10. Moore MB, Price EV, Knox JM, Elgin LW. Epidemiologic treatment of contacts to infectious syphilis. Public Health Rep. 1963;78:966-70.
11. Schroeter AL, Turner RH, Lucas JB, Brown WJ. Therapy for incubating syphilis. Effectiveness of gonorrhea treatment. JAMA. 1971;218(5):711-3.
12. Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients wtih new syphilis infections. AIDS. 2004;18(15):2075-9.
13. Kofoed K, Gerstoft J, Mathiesen LR, Benfield T. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis. 2006;33(3):143-8.
14. Palacios R, Jiménez-Oñate F, Aguilar M, et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44(3):197-201.
15. Clinical advisory: ocular syphilis in the United States. Centers for Disease Control and Prevention. http://www.cdc.gov/std/syphilis/clinicaladvisoryos2015.htm. Accessed on April 13, 2016.
16. Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for syphilis: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. doi:10.1001/jama.2016.4114.
17. Nelson HD, Glass N, Huffman L, et al. Screening for Syphilis: Brief Update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
18. Mishra S, Boily MC, Ng V, et al. The laboratory impact of changing syphilis screening from the rapid-plasma reagin to a treponemal enzyme immunoassy: a case-study from the Greater Toronto Area. Sex Transm Dis. 2011;38(3):190-6.
19. Binnicker MJ, Jespersen DJ, Rollins LO. Direct comparison of the traditional and reverse syphilis screening algorithms in a population with a low prevalence of syphilis. J Clin Microbiol. 2012;50(1):148-50.
20. ACOG-endorsed documents. American Congress of Obstetricians and Gynecologists. http://www.acog.org/Resources-And-Publications/Endorsed-Documents. Accessed April 12, 2016.
21. Aberg JA, Gallant JE, Ghanem KQ, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1-10.
22. Clinical preventive service recommendation: syphilis. American Academy of Family Physicians. http://www.aafp.org/patient-care/clinical-recommendations/all/syphilis.html. Accessed April 12, 2016.